SENS
The Newsroom
In The Media
Media Contacts
Leadership & Structure
Corporate Governance
Our Heritage
Diversity
Learning & Development
Strategic Alliances
Anti-retroviral Portfolio (ARVs)
Generics
Contact Us
Optimise Your Health
Addiction Awareness
Self Medication
Medical Tips
Medicine Safety
Package Inserts
Any Queries? Contact Us
Brand News
Brands At A Glance
Our Commitment
Single Exit Price
The Investment Case
Financial Reports
Financial Indicators
Shareholder Corner
Contact Investor Relations
SENS
Passion For Our
Community
Our Latest Initiatives
The Environment
Require Funding?
Contact Us
Careers At Adcock Ingram
Latest Opportunities
Thank you for accessing Adcock Ingram's corporate website. Our website offers a diverse range of information about our Company to help give you an understanding of who we are and what we have to offer.
Please
contact us
should you require any further information.
Jonathan Louw (CEO Adcock Ingram)
Group Audited Results 2012
Group Audited Results 2012
Results Presentation 2012
Webcast
Adcock Ingram today announced that the Centre for Drug Evaluation and Research of the US Food and Drug Administration has accredited the company’s Wadeville Manufacturing facility,
[READ MORE]
20
May
Monday
Su
Mo
Tu
We
Th
Fr
Sa
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
Latest Share Price
N/A cents
Percentage Change:
0.00
Code:
AIP
PE Ratio:
16.30
EY:
6.14
DY:
2.92
ZAR/USD:
9.3962
Interim Dividend
(cents):
115.00
Final Dividend
(cents):
86.00